Johnson & Johnson ordered to pay $40 million to two women in latest talc trial

Johnson & Johnson ordered to pay $40 million to two women in latest talc trial

Updated on 13 Dec 2025 Category: Business • Author: Scoopliner Editorial Team
हिंदी में सुनें

Listen to this article in Hindi

गति:

Johnson & Johnson ordered to pay $40 million for talc-related ovarian cancer, with plans to appeal the jury's verdict.


A California jury in the U.S. on Friday (December 12, 2025) awarded $40 million to two women who said Johnson & Johnson’s baby powder was to blame for their ovarian cancer.
The jury in Los Angeles Superior Court awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband after finding that Johnson & Johnson knew for years its talc-based products were dangerous but failed to warn consumers.
Erik Haas, Johnson & Johnson’s worldwide vice president of litigation, said in a statement the company plans to “immediately appeal this verdict and expect to prevail as we typically do with aberrant adverse verdicts.”
A spokesperson for the plaintiffs did not immediately respond to a request for comment.
Used for 40 years
Ms. Kent was diagnosed with ovarian cancer in 2014, according to court records. Ms. Schultz was diagnosed in 2018. Both women are California residents who say they used J&J’s baby powder after bathing for 40 years. Their treatments for ovarian cancer have involved major surgeries and dozens of rounds of chemotherapy, they testified at the trial.
In closing arguments that Reuters viewed on Courtroom View Network, Andy Birchfield, an attorney for the women, told the jury that Johnson & Johnson knew as far back as the 1960s that its product could cause cancer.
“Absolutely they knew, they knew and they were doing everything they could to hide it, to bury the truth about the dangers,” Mr. Birchfield said.
No evidence, says company
Allison Brown, an attorney for Johnson & Johnson, said the only people to tell Ms. Kent and Ms. Schultz that their cancers were caused by talc were their lawyers, as the alleged connection isn’t backed by any major U.S. health authority and there is no study that shows talc can migrate from the outside of the body to the reproductive organs.
“They don’t have the evidence in this case, and they hope you don’t mind,” Ms. Brown told the jury.
J&J is facing lawsuits from more than 67,000 plaintiffs who say they were diagnosed with cancer after using its baby powder and other talc products, according to court filings.
The company has said its products are safe, do not contain asbestos and do not cause cancer. J&J stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.
J&J has sought to resolve the litigation through bankruptcy, a proposal that has been rejected three times by federal courts, most recently in April. The bankruptcies had put most cases on hold. Brown and Kent’s cases are the first to go to trial since the latest Chapter 11 attempt was dismissed.
Before the bankruptcy attempts, J&J had a mixed record in talc trials, with verdicts as high as $4.69 billion awarded to women who said baby powder caused their ovarian cancer. The company has won some trials outright and had other verdicts reduced on appeal.
The majority of lawsuits involve ovarian cancer claims. Cases alleging talc caused a rare and deadly cancer called mesothelioma make up a smaller portion of the claims J&J is facing. The company has previously settled some of those claims but has not struck a nationwide settlement, so many lawsuits over mesothelioma have proceeded to trial in state courts in recent months.
In the past year, J&J has been hit with several substantial verdicts in mesothelioma cases, including one for more than $900 million in Los Angeles in October.

Source: The Hindu   •   13 Dec 2025

Related Articles

Nifty, Bank Nifty Trade Setup for December 15: 15 Key Things to Know
Nifty, Bank Nifty Trade Setup for December 15: 15 Key Things to Know

Key Nifty and Bank Nifty levels, options data, and market trends to watch before the opening bell on December 15. Max pain, …

Source: Moneycontrol | 15 Dec 2025
Madhusudan Kela Still Bullish on This SmallCap Stock Despite 34% Correction
Madhusudan Kela Still Bullish on This SmallCap Stock Despite 34% Correction

Investor Madhusudan Kela's Rs. 240 crore investment in Windsor Machines, a cleaning equipment manufacturer, despite a recent stock decline.

Source: Trade Brains | 15 Dec 2025
Ahead of the Curve: 10 Factors Shaping Stock Market Activity This Week
Ahead of the Curve: 10 Factors Shaping Stock Market Activity This Week

Indian stocks saw slight weekly losses due to foreign investor outflows & trade worries, offset by a US Fed rate cut. Global …

Source: The Economic Times | 14 Dec 2025
← Back to Home

QR Code Generator